Literature DB >> 19615335

A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors.

Xiaodong Xiao1, Yang Feng, Bang K Vu, Rieko Ishima, Dimiter S Dimitrov.   

Abstract

Isolated immunoglobulin CH2 domains were proposed as scaffolds for selection of binders with potential effector functions. We tested the feasibility of this approach by constructing a large (size 5 x 10(10)) library where all amino acids in two loops (BC and FG) were mutated to four residues (Y, A, D, or S). Three binders were selected from this library by panning against a gp120-CD4 complex. The strongest binder, m1a1, recognized specifically a highly conserved CD4i epitope and inhibited to various extents seven out of nine HIV-1 isolates from different clades. The loop BC and the conformational state of the scaffold are critical for its binding. These results provide a proof of concept for the potential of CH2 as a scaffold for construction of libraries containing potentially useful binders. The newly identified HIV-1 inhibitors could be further improved to candidate therapeutics and/or used as research reagents for exploration of conserved gp120 structures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19615335      PMCID: PMC2753272          DOI: 10.1016/j.bbrc.2009.07.044

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.

Authors:  Ramalakshmi Darbha; Sanjay Phogat; Aran F Labrijn; Yuuei Shu; Yijun Gu; Michelle Andrykovitch; Mei-Yun Zhang; Ralph Pantophlet; Loic Martin; Claudio Vita; Dennis R Burton; Dimiter S Dimitrov; Xinhua Ji
Journal:  Biochemistry       Date:  2004-02-17       Impact factor: 3.162

2.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 3.  Engineered CH2 domains (nanoantibodies).

Authors:  Dimiter S Dimitrov
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

4.  The binding site for C1q on IgG.

Authors:  A R Duncan; G Winter
Journal:  Nature       Date:  1988-04-21       Impact factor: 49.962

5.  Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Authors:  Maxime Moulard; Sanjay K Phogat; Yuuei Shu; Aran F Labrijn; Xiaodong Xiao; James M Binley; Mei-Yun Zhang; Igor A Sidorov; Christopher C Broder; James Robinson; Paul W H I Parren; Dennis R Burton; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

6.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

9.  Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition.

Authors:  Frederic A Fellouse; Christian Wiesmann; Sachdev S Sidhu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

10.  Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.

Authors:  R Beers; P Chowdhury; D Bigner; I Pastan
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 13.801

View more
  25 in total

Review 1.  Therapeutic proteins.

Authors:  Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2012

2.  Therapeutic antibodies, vaccines and antibodyomes.

Authors:  Dimiter S Dimitrov
Journal:  MAbs       Date:  2010-05-14       Impact factor: 5.857

Review 3.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

4.  The Shark Strikes Twice: Hypervariable Loop 2 of Shark IgNAR Antibody Variable Domains and Its Potential to Function as an Autonomous Paratope.

Authors:  Stefan Zielonka; Martin Empting; Doreen Könning; Julius Grzeschik; Simon Krah; Stefan Becker; Stephan Dickgießer; Harald Kolmar
Journal:  Mar Biotechnol (NY)       Date:  2015-05-24       Impact factor: 3.619

5.  Yeast display of engineered antibody domains.

Authors:  Qi Zhao; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2012

6.  Expression, purification, and characterization of engineered antibody CH2 and VH domains.

Authors:  Rui Gong; Weizao Chen; Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2012

Review 7.  Engineered Fc based antibody domains and fragments as novel scaffolds.

Authors:  Tianlei Ying; Rui Gong; Tina W Ju; Ponraj Prabakaran; Dimiter S Dimitrov
Journal:  Biochim Biophys Acta       Date:  2014-05-02

Review 8.  Candidate antibody-based therapeutics against HIV-1.

Authors:  Rui Gong; Weizao Chen; Dimiter S Dimitrov
Journal:  BioDrugs       Date:  2012-06-01       Impact factor: 5.807

Review 9.  Engineered Autonomous Human Variable Domains.

Authors:  Johan Nilvebrant; Peter M Tessier; Sachdev S Sidhu
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 10.  Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains.

Authors:  Weizao Chen; Rui Gong; Tianlei Ying; Ponraj Prabakaran; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Curr Drug Discov Technol       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.